Study on Behavioral Economics to Enhance ART Adherence in HIV Patients
The INMIND study aims to improve long-term adherence to antiretroviral treatment using behavioral economics.
Phase III
Infectious Disease / HIV
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The INMIND study explores innovative behavioral economics strategies to enhance adherence to antiretroviral treatment in HIV patients. If successful, it could redefine adherence interventions, prompting pharma companies to reassess their patient support frameworks.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor results from the SMART trial and subsequent implementation in other settings.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.